PepTalk 2017
PepTalk 2017

Antibody Drug Products 

Day 1 | Day 2 | Download Brochure 


Conference Short Courses*View Details 

Sunday, January 9 - 3:00 pm - 6:00 pm 

  • Protein Crystallization - Delineating Protein Structure
  • DoE and QbD: Tools for Optimizing the Bioprocess

Tuesday, January 11 - 4:30 pm - 7:30 pm 

Thursday, January 13 - 6:30 pm - 9:00 pm 

  • Rational Design of Protein Solutions


Antibody-based products currently revolutionizing therapeutics will be addressed, including antibody-drug conjugates, bispecific antibodies, and other novel constructs.  These new antibody designs are overcoming nagging challenges, such as size and penetration, and enhancing half-life, PK, and specificity. 

Join colleagues from around the world in this discussion of the exciting breakthroughs made possible by engineering advances, and see how cancer and other applications are progressing into a true therapeutic revolution.


1:00pm  Conference Registration


Innovating the Design of Antibody Therapeutics 

1:45  Chairperson’s Remarks

Mohan Srinivasan, Ph.D., Associate Director, Protein Chemistry, Biologics Discovery, Bristol-Myers Squibb Co.

1:50  Synthetic Polymers with Antibody-Like Affinity that Function in vitro and in vivo 

Kenneth Shea, Ph.D., Professor, Chemistry and Chemical Engineering, Biological and Materials Science, University of California, Irvine

General methods for the recognition of specific peptide sequences, proteins and related biological macromolecules remain a significant challenge. This talk will describe general protocols for creating synthetic polymer receptors for peptides and proteins with antibody-like affinity for biological macromolecules both in vitro and in vivo.

2:20  Drug Conjugation Site Modulates the Stability and Biological Activity of Antibody Drug Conjugates

Ben Shen, M.D., Scientist, Pharmacokinetics & Pharmacodynamics Sciences, Genentech Research & Early Development (gRED)

Antibody drug conjugates (ADCs) take advantage of the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thereby enhancing their anti-tumor activity with potentially reduced toxicity. Successful ADC development relies on optimization of antibody selection, linker stability, cytotoxic drug potency and mode of linker-drug conjugation to the antibody. This presentation will discuss the impact of drug conjugation site on ADC stability and biological activity. Understanding the underlying molecular mechanism offers important implication in developing optimal ADC for unmet medical needs.     

2:50  Innovative Strategies and Techniques for Late-Stage Screening of Therapeutic Biologics

Mohan Srinivasan, Ph.D., Associate Director, Protein Chemistry, Biologics Discovery, Bristol-Myers Squibb Co.

An in-depth characterization of biologics in the development phase is one of the key determinants of its success in clinic. But, it could also be the task that could cost the most time and money. A process of screening that could incorporate many methods to identify such potential development hurdles as an integral part of the late stage screening of leads, could vastly improve the success rates during the developmental phase. We will present novel techniques and data to support this approach.

Sponsored by
3:20 Expanding the ProteOn XPR36 Biosensor into a 36-ligand Array to Facilitate Epitope Binning and Epitope Mapping 
Yasmina Noubia Abdiche, Associate Research Fellow, Rinat-Pfizer
Here we demonstrate methods to expand the throughput of the ProteOn XPR36 biosensor allowing for several multiplexed formats that expedite detailed epitope binning and mapping studies. By arraying 36 disparate antibodies that target the same antigen, we generated pair-wise epitope binning data for a full 36 X 36 matrix in a single assay. By arraying biotinylated peptides we rapidly screened a panel of antibodies to identify those that bound to linear epitopes. We validated our binning and mapping data by performing similar assays on other label-free biosensor platforms. Applying alternative formats of the ProteOn interaction array enables a significantly higher number of assays to be conducted simultaneously than previously anticipated on this platform.

3:35  Refreshment Break, Exhibit and Poster Viewing

Engineering Multi-Specificity 

4:30  Dual-Affinity Re-Targeting (DART) Proteins: Production, Applications, and Platform Optimization

Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics, Inc.

Despite tremendous progress recently in the field of bispecific antibodies, several properties have remained less than optimal.  Primary among these are correct assembly, ease of production, stability and pharmacokinetic properties.  We have developed an elegant, best-in-class, platform that addresses each of these issues. Case studies of dual-affinity (DART) proteins optimized for oncology, autoimmune/inflammatory and infectious diseases applications will be presented.

5:00  TRIBODY: A Platform for Novel Antibody-Derived Biopharmaceuticals

Nico Mertens, Ph.D., M.B.A., Director Antibody Engineering, Biotecnol SA

Tribodies™ are antibody fragment manifolds based on fusion to Fab-chains. The molecular structure allows easy engineering of bispecific, bivalent bispecific, trispecific or multivalent reagents. Tribodies™ behave superior as compared to scFv-scFv constructs. This is probably due to better PK properties of these intermediate sized molecules, and to the multivalent targeting. Tribodies™ hold much potential to be developed as a new generation of biopharmaceuticals, as they can target multiple antigens with a single molecule.

5:30  Close of Day

Day 1 | Day 2 | Download Brochure 

Links to Companion Meetings

Pipeline 1 

Recombinant Protein Therapeutics 

Antibodies for the 21st Century